This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Magar RS, Purdy C, Hayward A, Einarson TR, Burnett AK.Cost-effectiveness Analysis of Histamine Dihydrochloride + Low Dose Interleukin-2 vs Standard of Care for Acute Myeloid Leukemia Patients in their First Complete Remission: a Uk Perspective. 12th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research: abstr. PCN83, 24 Oct 2009. Available from: URL: http://www.ispor.org/Events/Index.aspx?eventId=30
Purdy C, Magar RS, Hayward A, Einarson TR.Comparison of Two Methods to Determine Costs for Aml Patients in Remission: Model Validation From a Uk Perspective. 12th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research: abstr. PMC38, 24 Oct 2009. Available from: URL: http://www.ispor.org/Events/Index.aspx?eventId=30
EpiCept Corporation.New Data Supports Pharmacoeconomic Benefits of Ceplene(R). Media Release: 26 Oct 2009. Available from: URL: http://www.epicept.com
Rights and permissions
About this article
Cite this article
Ceplene + low-dose IL-2 dominates standard care for AML. Pharmacoecon. Outcomes News 591, 4 (2009). https://doi.org/10.2165/00151234-200905910-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200905910-00005